B. Riley Issues Optimistic Forecast for Electromed Earnings

Electromed, Inc. (NYSE:ELMD) – Equities research analysts at B. Riley raised their Q4 2026 earnings per share (EPS) estimates for Electromed in a research report issued to clients and investors on Thursday, November 13th. B. Riley analyst A. Schock now forecasts that the company will earn $0.32 per share for the quarter, up from their prior estimate of $0.29.

Several other equities analysts have also recently issued reports on ELMD. Lake Street Capital assumed coverage on shares of Electromed in a research report on Wednesday, August 27th. They set a “buy” rating and a $36.00 price target on the stock. Loop Capital set a $36.00 price objective on shares of Electromed in a research note on Wednesday, August 27th. Roth Capital reiterated a “buy” rating and set a $36.00 target price (up from $35.00) on shares of Electromed in a report on Thursday. Finally, Zacks Research downgraded Electromed from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Electromed presently has an average rating of “Buy” and an average price target of $36.50.

Electromed Trading Down 4.1%

ELMD stock opened at $25.27 on Monday. The stock has a market capitalization of $211.66 million, a price-to-earnings ratio of 33.69 and a beta of 0.40. Electromed has a 12-month low of $17.73 and a 12-month high of $35.56. The firm’s 50-day moving average price is $24.62 and its two-hundred day moving average price is $21.98.

Hedge Funds Weigh In On Electromed

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp increased its holdings in Electromed by 14.7% during the first quarter. Bank of New York Mellon Corp now owns 36,276 shares of the company’s stock valued at $866,000 after buying an additional 4,661 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Electromed during the 1st quarter valued at $394,000. XTX Topco Ltd grew its position in shares of Electromed by 57.4% during the 1st quarter. XTX Topco Ltd now owns 16,414 shares of the company’s stock valued at $392,000 after acquiring an additional 5,985 shares during the period. Russell Investments Group Ltd. lifted its position in Electromed by 557.0% during the first quarter. Russell Investments Group Ltd. now owns 7,969 shares of the company’s stock valued at $186,000 after purchasing an additional 6,756 shares in the last quarter. Finally, American Century Companies Inc. grew its holdings in Electromed by 32.5% during the first quarter. American Century Companies Inc. now owns 31,062 shares of the company’s stock valued at $741,000 after purchasing an additional 7,624 shares during the period. Hedge funds and other institutional investors own 40.82% of the company’s stock.

Insider Transactions at Electromed

In other Electromed news, Director Andrew Summers sold 62,561 shares of the business’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $24.32, for a total transaction of $1,521,483.52. Following the completion of the sale, the director directly owned 3,153 shares in the company, valued at $76,680.96. The trade was a 95.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 10.50% of the company’s stock.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.